Quince Therapeutics released FY2025 Semi-Annual Earnings on August 11 (EST) with actual revenue of USD 0 and EPS of USD -6.8585

Brief Summary

Quince Therapeutics announced its 2025 semi-annual financial results, reporting zero revenue, a net loss of $31.079 million, and an earnings per share (EPS) of -$6.8585.

Impact of The News

The financial briefing from Quince Therapeutics on its 2025 semi-annual performance provides a clear picture of its current operational phase and sets the stage for its future trajectory.